..


Business News

  • Written by Heidi Cuthbert


7 May 2018: Race Oncology Limited (“RAC”) released today a video interview with the Company’s new non-executive director, Dr John Cullity.

Dr Cullity trained as a haematology oncologist and became a specialist in the area of leukaemia. He has also held senior roles with Sanofi-Aventis and Schering-Plough in the US.

Based in New York, Dr Cullity now focuses on M&A and licensing transactions in the biopharma industry.

Commenting on Race Oncology’s first drug, Bisantrene, Dr Cullity said: “There is substantial opportunity for Bisantrene which is led by its activity in acute myeloid leukaemia.”

“Bisantrene has been shown to be active through immune-oncology pathways, which are so relevant to blockbuster agents that are currently being marketed by major pharmaceutical companies,” noted Dr Cullity.

“Additionally, it has unparalleled safety, particularly cardiac safety, which is so relevant and much sought-after by doctors within the anthracycline class.

He concluded: “Altogether, it’s a compelling package.”

In terms of the specific value he brings to the Race board, Dr Cullity noted: “I can help in several ways – firstly, through the evaluation of transactions as they come to light for Bisantrene with mid-to-large pharmaceutical companies.”

“Secondly, as the company considers additional assets that it might bring to build further investor value, I can assist with related assessment and negotiation.”

About Bisantrene

Bisantrene is a small-molecule chemotherapy drug related to the anthracyclines, the most frequently prescribed cancer drugs and first line of treatment for many cancers, but has been shown to have greatly reduced cardiac toxicity. Bisantrene was tested in more than 40 clinical studies before it was lost in a series of pharmaceutical mergers in the 1990s. The initial clinical opportunity for Bisantrene is for relapsed/refractory AML patients. Race owns two patents on the drug, both of which have received notice of allowance in the US, and has been granted an Orphan Drug Designation in the US for AML, which confers seven years of market exclusivity in US from date of FDA approval.

About Race Oncology (RAC.ASX)

Race Oncology is a specialty pharmaceutical company that listed on the Australian Securities Exchange (ASX) in July 2016. Race’s business model is to pursue later-stage drug assets in the cancer field that have been overlooked by big pharma. The company’s first asset is Bisantrene, a chemotherapy drug that was the subject of more than 40 phase II clinical studies during the 1980s and 1990s, then lost in a series of big pharma mergers.

 



g

Why Should You Hire a Professional for Investigating Fraud?

Looking for a professional to investigate a business or employment fraud? How to choose the right person to do the job for you?Confused? Well, not anymore. You would always need assistance and advice ...

Achieving the Perfect Balance of SEO and Creative Content is just a Few Steps Away

If you want an appropriate description of today’s online marketing world, in the search engine optimization kingdom, it may somewhat fit along the lines -- content is the king. Basically, it means tha...

Get Your Hands on The Perfect Shipping Container Today

A shipping container is such a blessing in disguise! It comes in handy for both temporary as well as long term storage, or say mobile offices, or even as temporary building options. They are extensive...

Is a flexible workforce the way of the future?

In short, “Yes,” says Joint Managing Director of Citrus Group, Paul Smith. By nature, working in a contact centre “isn’t the easiest job in the world,” says Paul. Allowing staff to work flexible hou...

Careers Campsite

‘Careers Campsite’ to bring over 100 job opportunities and career advice directly to Western Sydney youth tomorrow   Skillsroad, Australia’s number one destination for career advice and entry-leve...

United Co.: Leading young Australian entrepreneur building start up precinct

United Co., set in the heart of buzzing Fitzroy, is Melbourne’s newest business and innovation centre with collaborative work spaces and luxury offices which has been masterfully created out of the ...

Politics

Scott Morrison - Breaking Ground on Western Sydney Airport

Construction on Western Sydney Airport will begin today – boosting jobs, creating much-needed infrastructure and strengthening the economy.   Prime Minister Scott Morrison said the Western Sydney ...

Scott Morrison - More choice for Australian families

Australian families will have choice and equity in education as the Morrison Government guarantees funding to the non-government school sector. The Australian Government has accepted all the recom...

Dutton - Labor/Green witch-hunt comes up empty

Despite Labor’s best efforts in hyping up the so-called “au pair” Senate inquiry, the farcical and shambolic witch-hunt has come up with nothing except findings that mirror the Labor Party’s initial...

Travel

Holiday Hacks: How to beat the travel companies at their own game

HACK YOUR WAY TO A CHEAPER HOLIDAY How to beat the travel companies at their own game and save money during the next school holidays   19 September 2018: As any parent who’s tried to book a holid...

Experience European Glamour with Ecruising

In May 2019, Ecruising is inviting travellers on an exciting itinerary that includes not one, but two, quintessential French Riviera events – the high-octane Monaco Grand Prix and the iconic Canne...

Factors to Consider When Buying a Campervan

You’ve been waiting to buy a Winnebago campervan and now it’s your chance. You’ve saved up and you’re ready to start living the road trip lifestyle. You’re in for a great time and adventure. Of cour...

You might also like